Citations

Clear

554 citation(s) found for "Li, Gerald".

A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).
Stinchcombe, Tom, Zhang, Ying J., Schiller, Joan H. , Curran, Walter J. , Movsas, Benjamin , Clamon, Gerald H., Blumenschein, George R. , Ready, Neal , Akerley, Wallace , Cohen, Harvey Jay, Wang, Xiaofei F., Stinchcombe, Thomas E. , Vokes, Everett E. , Bradley, Jeffrey D. , Schild, Steven E. , Govindan, Ramaswamy , Socinski, Mark A. , Pang, Herbert

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8508-8508

10.1200/jco.2016.34.15_suppl.8508 Get It

Relation of depressive and anxious symptoms to overall distress and mortality in patients undergoing radiation therapy.
Brett, Christopher , Strong, Gerald, Hintenlang, Lauren L., Whitaker, D., Jagadesh, Niveditha , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e21567-e21567

10.1200/jco.2017.35.15_suppl.e21567 Get It

e21567 Background: For patients diagnosed with cancer, depression and anxiety represent a common and significant burden, which has been proposed to not only affect quality of life but to potentially shorten duration of life as well. This study examines the influence of patient reported symptoms of anxiety and depression on overall distress and mortality in patients undergoing radiation therapy. Methods: As part of their intake paperwork, patients undergoing radiation therapy completed distress screening that included 29 questions regarding their level of concern with various factors related to their care as well as their overall distress level. This information and other parameters including demographics, site of primary disease, use of chemotherapy, presence of metastasis, and last known status were recorded for analysis. Answers regarding degree of concern for “feeling down or depressed”, “loss of interest in my usual activities”, and “feeling nervous or anxious” were examined for influence on study endpoints. Results: Results for final analysis were available from 519 patients undergoing therapy from April 2010 to May 2016. The cohort’s average age was 66yrs, 71% were treated curatively, and 29% were treated palliatively. The most common treatment sites were breast (27%), thorax (16%), H&N (12%), GU (12%), GI (10%), and CNS (7%). Significant correlation was found between level of concern with symptoms of anxiety and depression and level of overall distress (P < 0.001, Kruskal-Wallis Rank Sum Test). Significance remained on separate analysis of curative and palliative subgroups. No significant correlation was found for 1 or 2 year survival on either single or multivariate analysis of curative or palliative patients. Conclusions: Depression and anxiety are common conditions among cancer patients, and can contribute significantly to their overall distress. Although no effects on mortality were demonstrated on initial follow-up of this cohort, it remains evident that attention to emotional well-being is critical in the care of such patients. Additional investigations can be pursued regarding ideal interventions for patients identified by such screening.
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
Shih, Kent C. , Patel, Manish R. , Butowski, Nicholas , Kizilbash, Sani H. , Bacha, Jeffrey , Brown, Dennis , Steinø, Anne, Schwartz, Richard S. , Kanekal, Sarath, Lopez, Lorena, Burris, Howard A. , Kizilbash, Sani H , Falchook, Gerald Steven

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2063-2063

10.1200/jco.2016.34.15_suppl.2063 Get It

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen, Robert W., Ansell, Stephen M. , Gallamini, Andrea , Grigg, Andrew , Sureda, Anna M., Feldman, Tatyana , Özdemir, Evren , Offner, Fritz , Engley, Gerald, Fenton, Keenan , Lee, Shih-Yuan, Jolin, Hina, Gautam, Ashish , Hutchings, Martin , Connors, Joseph M. , Savage, Kerry J. , Collins, Graham P. , Sureda, Anna , Ghosh, Nilanjan , Fosså, Alexander

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7539-7539

10.1200/jco.2018.36.15_suppl.7539 Get It

A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Azad, Nilofer S. , Dy, Grace K. , Gallagher, Denise , Brennen, Caden, Cutler, David L. , Kramer, Douglas, Kwan, Rudolf, Fetterly, Gerald J., Adjei, Alex A. , Jimeno, Antonio , Wee, Wen , Lam, Elaine T. , Diamond, Jennifer R. , Opyrchal, Mateusz , Chan, Wing‐Kai

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2526-2526

10.1200/jco.2018.36.15_suppl.2526 Get It

Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert W., Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Straus, David J. , Younes, Anas , Fenton, Keenan , Manley, Thomas, Engley, Gerald, Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay K. , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J. , Connors, Joseph M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7541-7541

10.1200/jco.2018.36.15_suppl.7541 Get It

Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
Shih, Kent C. , Patel, Manish R. , Butowski, Nicholas , Kizilbash, Sani H. , Bacha, Jeffrey , Brown, Dennis , Schwartz, Richard S. , Kanekal, Sarath, Constant, John C.I., Burris, Howard A. , Kizilbash, Sani H , Falchook, Gerald Steven , Jones, Suzanne Fields

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2061-2061

10.1200/jco.2018.36.15_suppl.2061 Get It

Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Pellikka, Patricia A. , She, Lilin , Holly, Thomas A., Lin, Grace , Pai, Ramdas G. , Bonow, Robert O. , Pohost, Gerald M., Panza, Julio A. , Berman, Daniel S. , Prior, David , Asch, Federico M. , Borges‐Neto, Salvador , Grayburn, Paul , Al‐Khalidi, Hussein R. , Desvigne‐Nickens, Patrice , Lee, Kerry L. , Oh, Jae K. , Pellikka, Patricia A , Varadarajan, Padmini , Miszalski‐Jamka, Karol , Velazquez, Eric J.

Mayo Clinic

JAMA Network Open | September 3, 2018 | Volume: 1 | Issue: 4 | Pages: e181456

10.1001/jamanetworkopen.2018.1456 | PMID 30646130 Get It

Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs
Whitfield, Kyly C. , Adamolekun, Bola, Bergeron, Gilles, Brown, Kenneth H. , Cox, Lorna, Fattal‐Valevski, Aviva , Frank, Elizabeth L., Hiffler, Laurent , Hlaing, Lwin Mar , Kapner, Hallie, Mousavi, Maral P. S. , Roth, Daniel , Tsaloglou, Maria‐Nefeli , Wieringa, Frank T. , Combs, Gerald F., Fischer, Philip R. , Bourassa, Megan W. , Bettendorff, Lucien , Jefferds, Maria Elena , Kounnavong, Sengchanh

Mayo Clinic

Annals of the New York Academy of Sciences | August 28, 2018 | Volume: 1430 | Issue: 1 | Pages: 3-43

10.1111/nyas.13919 | PMID 30151974 Get It

AbstractThiamine is an essential micronutrient that plays a key role in energy metabolism. Many populations worldwide may be at risk of clinical or subclinical thiamine deficiencies, due to famine, reliance on staple crops with low thiamine content, or food preparation practices, such as milling grains and washing milled rice. Clinical manifestations of thiamine deficiency are variable; this, along with the lack of a readily accessible and widely agreed upon biomarker of thiamine status, complicates efforts to diagnose thiamine deficiency and assess its global prevalence. Strategies to identify regions at risk of thiamine deficiency through proxy measures, such as analysis of food balance sheet data and month‐specific infant mortality rates, may be valuable for understanding the scope of thiamine deficiency. Urgent public health responses are warranted in high‐risk regions, considering the contribution of thiamine deficiency to infant mortality and research suggesting that even subclinical thiamine deficiency in childhood may have lifelong neurodevelopmental consequences. Food fortification and maternal and/or infant thiamine supplementation have proven effective in raising thiamine status and reducing the incidence of infantile beriberi in regions where thiamine deficiency is prevalent, but trial data are limited. Efforts to determine culturally and environmentally appropriate food vehicles for thiamine fortification are ongoing.
Abstract 991: Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior
Legendre, Christophe, Gooden, Gerald , Johnson, Kyle N., Petricoin, Emanuel F. , O’Shaughnessy, Joyce , Osborne, C., Bernstein, Mark, Salhia, Bodour , Tew, Ben Yi , Triche, Timothy J. , Martinez, Rae Anne , Pierobon, Mariaelena , Schroeder, Mark A. , Daniel, J. , Sarkaria, Jann N. , Toms, Steven A.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 991-991

10.1158/1538-7445.am2018-991 Get It

Abstract Despite recent advances in cancer therapy, options for central nervous system metastasis (CM) remain limited and patient outcomes are dismal. The lack of tumor models that reflect the heterogeneity and complexity of human CM tumors is a barrier to understanding the underlying biology and to developing novel therapies. Here, we report the development and characterization of 39 patient derived xenograft (PDX) models of CM tumors with histological subtypes representing the disease spectrum. The PDX models successfully grew both in the flank and brains of mice, and retained their histology regardless of the site of implantation. Brain metastasis also formed in 5/12 models after intra-cardiac injection. Multi-omic analysis of the PDX tumor and the patient-matched CM tumor showed that PDXs largely retained the molecular profiles of the tumor from which they were derived, including the retention of aberrations in key driver genes and signaling pathways. PDXs differed primarily from the ungrafted patient tumors by a downregulation in immunity-related pathways, which was expected due to the use of an immuno-compromised host, arguing for the validity of using the flank as a site of implantation. Integrated analysis of mutations and gene expression changes in CM revealed an upregulation of neuronal signaling and DNA damage response, and downregulation of calcium signaling and inflammation. We also assessed the clonal evolution of the PDX from the original patient CM by tracing variant allele frequencies in copy number neutral regions. We found that the PDX tumors were heterogeneous and comprised of multiple tumor clones that were either unique or in common with the original tumor, and displayed evidence of clonal expansion. Two PDXs that underwent phylogeny assessment showed evidence of minor clone expansion. One such PDX was a tumor from a Her2+ breast cancer (CM13), which largely did not molecularly resemble its matched patient tumor but was confirmed to have some shared expressed variants. The PDX was nearly copy number neutral, which included loss of the Her2 amplicon, and had few mutations compared with its parent tumor. Most noteworthy, is that CM13 displayed unique molecular patterns, aggressive growth and was highly metastatic in vivo. From the flank, it led to multiple metastases, including micrometastasis in the brain. This suggests that minor clone takeover may confer tumor aggressiveness and potentiate brain metastasis. The large and diverse repertoire of PDXs developed and characterized in this study provides a new set of tools that will help deepen our understanding of CM and improve preclinical testing for CM therapies. Our data also show that expansion of minor clones could confer aggressive tumor behavior and may be important in tumor evolution in PDX models and human cancers. Citation Format: Ben Yi Tew, Christophe Legendre, Tim Triche, Gerald C. Gooden, Kyle N. Johnson, Rae Anne Martinez, Emanuel F. Petricoin, Mariaelena Pierobon, Joyce O'Shaughnessy, Cindy Osborne, Mark A. Schroeder, Daniel J. Ma, Mark Bernstein, Jann N. Sarkaria, Steven A. Toms, Bodour Salhia. Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 991.